Rockefeller University Press

Table I

TCR Vα Usage in Mutant TCR-β Transgenic Mice

	Percent of CD4⁺				Percent of CD8⁺
	Vα2⁺	Vα3.2⁺	Vα8⁺	Vα11⁺	Vα2⁺	Vα3.2⁺	Vα8⁺	Vα11⁺
β	22.7 ± 1.0	0.7 ± 0.2	3.0 ± 0.1	1.5 ± 0.4	7.7 ± 1.8	1.0 ± 0.1	4.5 ± 0.1	1.2 ± 0.2
β-loop⁻	22.7 ± 0.9	0.5 ± 0.1	2.6 ± 0.3	2.3 ± 0.3	7.6 ± 1.1	1.4 ± 0.6	3.6 ± 0.7	2.0 ± 0.3

	Percent of CD4⁺				Percent of CD8⁺
	Vα2⁺	Vα3.2⁺	Vα8⁺	Vα11⁺	Vα2⁺	Vα3.2⁺	Vα8⁺	Vα11⁺
β	22.7 ± 1.0	0.7 ± 0.2	3.0 ± 0.1	1.5 ± 0.4	7.7 ± 1.8	1.0 ± 0.1	4.5 ± 0.1	1.2 ± 0.2
β-loop⁻	22.7 ± 0.9	0.5 ± 0.1	2.6 ± 0.3	2.3 ± 0.3	7.6 ± 1.1	1.4 ± 0.6	3.6 ± 0.7	2.0 ± 0.3

Lymph node cells from TCR-β (β) or mutant TCR-β (β-loop⁻) transgenic mice were triple stained with the FITC-labeled anti-Vα Abs, anti-CD4– PE, and anti-CD8–Cy5. Results (three mice per group) are expressed as the percentage of stained cells ± SD.

View Large

This Feature Is Available To Subscribers Only